| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2530.7B | ¥2258.9B | +12.0% |
| Operating Income | ¥335.8B | ¥319.6B | +5.1% |
| Ordinary Income | ¥398.5B | ¥330.8B | +20.5% |
| Net Income | ¥283.4B | ¥244.0B | +16.1% |
| ROE | 9.3% | 8.7% | - |
FY2025 Q3 results show revenue of 253.1 billion yen (YoY +12.0%), operating income of 33.6 billion yen (YoY +5.1%), ordinary income of 39.9 billion yen (YoY +20.5%), and net income of 28.3 billion yen (YoY +16.1%). The company demonstrated solid top-line growth driven by geographic expansion and M&A consolidations, while profitability metrics remained healthy with gross margin at 56.2% and operating margin at 13.3%. The divergence between operating income growth (+5.1%) and ordinary income growth (+20.5%) reflects significant contributions from non-operating items including dividend income of 4.4 billion yen, interest income of 0.8 billion yen, and foreign exchange gains of 1.5 billion yen. Total assets increased to 460.7 billion yen from 437.0 billion yen, primarily due to goodwill additions from acquisitions totaling 33.6 billion yen in Asia and Europe segments. Equity ratio stands at 66.2%, maintaining a conservative capital structure, though notable shifts occurred in debt maturity profile with short-term borrowings rising 180.0 billion yen (+255.8%) while long-term debt decreased 16.4 billion yen (-92.0%).
Revenue increased 27.2 billion yen (+12.0% YoY) to 253.1 billion yen, driven by both organic growth and inorganic expansion through M&A. The Asia segment recorded the highest absolute growth with sales rising 22.5 billion yen (+30.8%) to 95.5 billion yen, reflecting the consolidation of Yu Yan Sang International subsidiary acquired in Q1, which contributed goodwill of 32.3 billion yen. Europe segment sales increased 3.9 billion yen (+28.8%) to 17.3 billion yen, supported by the acquisition of Mono company in Q2 adding goodwill of 1.4 billion yen. Japan segment, representing the core domestic business, showed modest growth of 0.4 billion yen (+0.3%) to 130.2 billion yen, indicating stable but mature domestic demand. America segment sales rose marginally 0.7 billion yen (+4.4%) to 16.8 billion yen. Geographic diversification progressed with international segments now accounting for approximately 48.5% of total sales compared to domestic Japan's 51.5%.
On the profit side, operating income grew 1.6 billion yen (+5.1%) to 33.6 billion yen, lagging revenue growth due to increased SG&A expenses which rose to 108.7 billion yen, representing 43.0% of sales. The operating margin contracted slightly from prior period levels, suggesting integration costs or investment spending associated with acquired entities. Segment operating profit analysis shows Asia contributed 13.3 billion yen (+26.4% YoY), Japan 18.0 billion yen (-2.8% YoY), America 1.0 billion yen (-6.2% YoY), and Europe 0.6 billion yen (-40.4% YoY), indicating profit mix shifts toward Asian operations while domestic and European profitability faced headwinds. A non-recurring impairment loss of 16 million yen was recorded in the Japan segment during the period.
Ordinary income expanded 6.8 billion yen (+20.5%) to 39.9 billion yen, significantly outpacing operating income growth due to net non-operating gains of approximately 6.3 billion yen. Key non-operating contributors include dividend income of 4.4 billion yen, interest income of 0.8 billion yen, and foreign exchange gains of 1.5 billion yen, partially offset by interest expenses of 0.9 billion yen. Net income reached 28.3 billion yen (+16.1% YoY), with profit before tax of 38.8 billion yen yielding an effective tax burden ratio of approximately 72.9%. The gap between ordinary income (39.9 billion yen) and net income (28.3 billion yen) reflects normal tax incidence without material extraordinary items below the line.
This represents a revenue up, profit up pattern, though profit growth trails revenue growth due to elevated operating expenses and integration-related costs from recent acquisitions.
Japan segment generated revenue of 130.2 billion yen and operating income of 18.0 billion yen, representing the largest segment by revenue share at 51.5% and operating profit share at 54.7%, establishing it as the core business. Operating margin for Japan stands at 13.8%, representing healthy profitability despite year-over-year operating income decline of 2.8%. Asia segment produced revenue of 95.5 billion yen with operating income of 13.3 billion yen, yielding an operating margin of 13.9%, slightly above Japan's margin and showing strong momentum with operating income growth of 26.4% YoY driven by the Yu Yan Sang consolidation. America segment recorded revenue of 16.8 billion yen and operating income of 1.0 billion yen with margin of 6.0%, materially below other segments and declining 6.2% YoY, indicating margin pressure in this market. Europe segment achieved revenue of 17.3 billion yen but operating income of only 0.6 billion yen, translating to a notably low margin of 3.3% and representing a sharp 40.4% profit decline YoY despite strong revenue growth, suggesting integration challenges or investment phase costs from the Mono acquisition. The margin differential is material, with Japan and Asia maintaining mid-teens profitability while America and Europe operate at mid-to-low single-digit margins, highlighting geographic profit quality variance and the need for operational improvement in Western markets.
[Profitability] ROE of 9.3% remained stable year-over-year, supported by net profit margin of 11.2% (net income 28.3 billion yen divided by revenue 253.1 billion yen) and operating margin of 13.3%. DuPont decomposition shows ROE of 9.3% driven by net margin of 11.2%, asset turnover of 0.549, and financial leverage of 1.51 times, indicating conservative capital structure with profitability primarily generated through margin rather than asset velocity or leverage. EBIT margin stands at 13.3% with interest burden ratio of 1.155 and tax burden ratio of 0.729, reflecting limited interest drag and normal tax incidence. Gross profit margin reached 56.2%, demonstrating strong pricing power or cost efficiency in core operations. [Cash Quality] Cash and deposits totaled 74.1 billion yen against short-term debt of 25.0 billion yen, providing cash coverage of 2.96 times for short-term borrowings. However, working capital metrics show deterioration with receivables turnover suggesting extended collection periods and inventory levels rising to 37.3 billion yen. [Investment Efficiency] Total asset turnover of 0.549 reflects capital-intensive pharmaceutical operations, consistent with industry characteristics but indicating room for efficiency improvement. Goodwill and intangible asset additions from M&A activities totaling 33.6 billion yen will require monitoring for impairment risk and return realization. [Financial Health] Equity ratio of 66.2% represents strong solvency with total equity of 304.9 billion yen supporting total assets of 460.7 billion yen. Current ratio of 203.1% and quick ratio of 169.1% indicate robust short-term liquidity. Debt-to-equity ratio of 0.09 confirms conservative leverage, though interest coverage ratio of 36.8 times (EBIT 33.6 billion yen divided by interest expense 0.9 billion yen) demonstrates ample earnings protection for debt service.
Cash and deposits increased 14.3 billion yen year-over-year to 74.1 billion yen, reflecting accumulation despite significant M&A outflows for acquisitions. Operating profit growth of 1.6 billion yen and strong profitability contributed to cash generation capacity, though actual operating cash flow figures are not disclosed for the quarterly period. Working capital movements show mixed signals with accounts receivable rising to 53.8 billion yen and inventories increasing to 37.3 billion yen, suggesting cash tied up in operating cycle and potential efficiency concerns. On the investing side, balance sheet analysis indicates substantial cash deployment for acquisitions generating goodwill of 33.6 billion yen, representing major strategic investment activity during the nine-month period. Financing activities show notable restructuring with short-term borrowings surging 18.0 billion yen to 25.0 billion yen while long-term borrowings decreased 16.4 billion yen to 1.4 billion yen, indicating debt maturity profile shift toward short-term funding. The short-term liabilities ratio of 94.6% highlights refinancing exposure, though cash coverage of 2.96 times against short-term debt provides cushion. Net debt position remains modest given total interest-bearing debt of 26.5 billion yen against cash of 74.1 billion yen, implying net cash position of 47.6 billion yen and strong balance sheet flexibility for ongoing strategic investments or shareholder distributions.
Ordinary income of 39.9 billion yen versus operating income of 33.6 billion yen indicates non-operating net contribution of approximately 6.3 billion yen, representing 15.8% uplift to operating profit and 2.5% of revenue. This comprises primarily equity method gains, dividend income of 4.4 billion yen, interest income of 0.8 billion yen, and foreign exchange gains of 1.5 billion yen, partially offset by interest expenses of 0.9 billion yen and other non-operating costs. The dividend and interest income streams suggest investment portfolio holdings contributing recurring non-operating earnings, while FX gains of 1.5 billion yen introduce volatility depending on exchange rate movements. Non-operating income of 6.3 billion yen represents 2.5% of total revenue, a material but not excessive proportion, though reliance on dividend income and FX gains raises questions about earnings sustainability if market conditions shift. The operating earnings base of 33.6 billion yen provides the core recurring foundation, with non-operating items enhancing but not substituting for operational performance. One-time factors include the 16 million yen impairment loss in Japan segment, immaterial to overall results. Without disclosed operating cash flow data, direct accruals quality assessment is constrained, though the strong cash position of 74.1 billion yen and healthy current ratio of 203.1% suggest underlying cash generation supports reported earnings. However, working capital deterioration indicated by rising receivables and inventories warrants monitoring for potential earnings quality concerns if collections or inventory turnover continue weakening.
Full-year guidance targets revenue of 340.5 billion yen, operating income of 40.5 billion yen, and ordinary income of 46.5 billion yen. Q3 cumulative progress shows revenue achievement of 74.3% (253.1 billion yen of 340.5 billion yen target), operating income achievement of 82.9% (33.6 billion yen of 40.5 billion yen target), and ordinary income achievement of 85.7% (39.9 billion yen of 46.5 billion yen target). At the standard three-quarter mark of 75%, operating income and ordinary income are tracking 7.9 percentage points and 10.7 percentage points ahead of pace respectively, indicating conservative guidance or front-loaded profitability. Revenue progress of 74.3% slightly trails the 75% benchmark by 0.7 percentage points, suggesting modest fourth-quarter acceleration needed or potential minor shortfall risk. The operating income run-rate implies Q4 operating income of approximately 6.9 billion yen required to meet full-year target, compared to Q3 nine-month actual of 33.6 billion yen, representing deceleration which may reflect seasonality or planned investment timing. Ordinary income similarly requires Q4 contribution of 6.6 billion yen, achievable given the strong non-operating income trends observed. Full-year EPS guidance of 146.04 yen compares to nine-month actual of 125.15 yen, implying Q4 EPS contribution of approximately 20.89 yen, which appears reasonable given historical patterns. The annual dividend forecast of 23.00 yen comprises interim dividend of 16.00 yen and expected year-end dividend of 20.00 yen, though this represents an inconsistency as 16.00 plus 20.00 totals 36.00 yen; clarification may be needed on interim versus second-quarter interim treatment. Overall guidance appears on track with profit metrics running ahead of schedule, though revenue execution in Q4 warrants attention to ensure full-year target achievement.
Annual dividend forecast stands at 23.00 yen per share for the full fiscal year. Based on full-year forecast EPS of 146.04 yen, the payout ratio calculates to 15.8%, representing a conservative distribution policy with substantial earnings retention for reinvestment. Comparing to the nine-month actual EPS of 125.15 yen and annualizing the 23.00 yen dividend yields a payout ratio of approximately 30.1% when adjusted for partial-year earnings, suggesting the company maintains flexibility in dividend policy relative to earnings trajectory. Year-over-year dividend comparison is not explicitly provided in the dataset, preventing assessment of dividend growth trends. No share buyback program information is disclosed for the current period, indicating dividends represent the sole form of cash return to shareholders. Total return ratio therefore equals the payout ratio at 15.8% based on forecast earnings, leaving significant cash flow retention of 84.2% for organic growth investment, M&A activity, or balance sheet strengthening. The conservative payout ratio of 15.8% provides substantial dividend sustainability cushion even if earnings face headwinds, supported by strong cash position of 74.1 billion yen and robust equity base of 304.9 billion yen generating ample coverage. The dividend policy appears oriented toward growth investment given active M&A strategy evidenced by 33.6 billion yen goodwill additions, with shareholder distributions maintained at modest but stable levels.
Refinancing risk emerges as the primary financial concern with short-term liabilities ratio reaching 94.6% of total liabilities and short-term borrowings surging 255.8% year-over-year to 25.0 billion yen while long-term debt collapsed 92.0% to 1.4 billion yen. This debt maturity concentration creates exposure to interest rate fluctuations and credit market conditions upon refinancing, though current cash coverage of 2.96 times and interest coverage of 36.8 times provide near-term protection. Goodwill impairment risk warrants close monitoring given 33.6 billion yen of goodwill additions from recent M&A activity, particularly the 32.3 billion yen Yu Yan Sang acquisition and 1.4 billion yen Mono acquisition. Integration execution challenges and realization of projected synergies will determine whether carrying values remain supported, with Europe segment's 40.4% operating profit decline despite revenue growth signaling potential stress. Working capital management deterioration poses operational risk as receivables and inventory levels rise, with quality metrics flagging material DSO, DIO, and cash conversion cycle degradation. Extended collection periods tie up cash and increase bad debt exposure, while inventory buildup raises obsolescence risk and carrying costs, particularly relevant in pharmaceutical and health products sectors with product lifecycle and expiration considerations. These working capital headwinds could strain liquidity if not addressed through enhanced collection efforts and inventory optimization.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: The company's ROE of 9.3% significantly outperforms the pharmaceutical industry median of -35.8% for 2025-Q3, placing it in a strong competitive position. Operating margin of 13.3% substantially exceeds the industry median of -218.2%, demonstrating superior operational efficiency and cost management relative to peer pharmaceutical companies. Net profit margin of 11.2% contrasts sharply with industry median of -216.8%, highlighting the company's ability to generate consistent bottom-line profitability while many industry participants face losses.
Financial Health: Equity ratio of 66.2% closely aligns with industry median of 67.8%, indicating comparable capital structure conservatism within sector norms. Current ratio of 203.1% falls well below industry median of 662.0%, though remains healthy in absolute terms at 2.0 times coverage, suggesting the company operates with tighter but adequate liquidity management compared to more conservative industry peers.
Efficiency: Asset turnover of 0.549 substantially exceeds industry median of 0.17, demonstrating superior asset utilization and revenue generation efficiency per unit of invested capital. This metric positions the company as a high-efficiency operator within a capital-intensive pharmaceutical sector. Inventory turnover of approximately 130 days (calculated from balance sheet) compares favorably to industry median of 281.6 days, indicating faster inventory velocity and working capital efficiency.
Growth: Revenue growth of 12.0% year-over-year significantly outpaces industry median decline of -12.5%, establishing the company as a growth leader through both organic expansion and M&A execution while sector peers face contraction. EPS growth of 15.4% substantially exceeds industry median decline of -6.0%, reflecting strong earnings momentum.
The company demonstrates exceptional relative performance across profitability, efficiency, and growth dimensions, operating well above industry benchmarks and positioned in the top quartile of pharmaceutical sector participants based on fundamental financial metrics.
(Industry: Pharmaceutical sector, N=13 companies for most metrics, Comparison period: 2025-Q3, Source: Proprietary analysis)
The company exhibits strong fundamental performance with revenue growth of 12.0% substantially outpacing the pharmaceutical industry median decline of 12.5%, while maintaining industry-leading profitability with operating margin of 13.3% versus sector median of negative 218.2%. Geographic diversification strategy shows tangible progress with international segments expanding to 48.5% of revenue mix, driven by strategic M&A execution adding 33.6 billion yen in goodwill from Asia and Europe acquisitions that enhance market access and product portfolio breadth.
Financial structure warrants attention as debt maturity profile shifted materially toward short-term funding, with short-term borrowings increasing 255.8% to 25.0 billion yen while long-term debt decreased 92.0% to 1.4 billion yen, creating refinancing exposure despite strong interest coverage of 36.8 times and cash coverage of 2.96 times indicating near-term debt service capacity remains adequate. Working capital efficiency deterioration represents an operational concern with receivables and inventory levels rising, though strong cash generation capacity evidenced by 74.1 billion yen cash position and robust 66.2% equity ratio provide financial flexibility to address operational optimization needs.
Full-year guidance progress tracking above pace for profitability metrics with operating income at 82.9% and ordinary income at 85.7% of annual targets through three quarters suggests potential for guidance upward revision or conservative forecasting, while dividend policy at 15.8% payout ratio provides substantial reinvestment capacity supporting ongoing M&A strategy and growth investments while maintaining shareholder distributions at sustainable levels with significant upside flexibility.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.